Summary of Novanta Incorporated Q2 2026 Earnings Call

1Key Financial Results and Metrics

Organic Sales Growth: 9% year-over-year; 10% reported growth.

Adjusted EBITDA: Increased by 16% to $60.7 million, with a margin of nearly 23% (up 120 basis points YoY).

Adjusted Gross Margin: 47%, up 100 basis points YoY.

Adjusted EPS: $0.89, a 17% increase from the previous year.

Operating Cash Flow: $65 million for Q2, with year-to-date cash flow of $117 million, surpassing all of 2025.

Debt Position: Gross debt of $239 million, with a net debt of negative $480 million.

2Strategic Updates and Business Highlights

Acquisition of Riverpoint Medical: Closed at the end of July; expected to significantly enhance Novanta's position in minimally invasive surgery, doubling the recurring medical consumable business to approximately $300 million.

Innovation and New Products: New product revenue grew over 50% in Q2, contributing to a vitality index of approximately 29% of sales.

Manufacturing Strategy: Completed moves and closures of two factories; announced two additional closures by Q1 2027 to streamline operations and reduce costs.

Segment Performance:

Medical Solutions segment grew 8.6% YoY; advanced surgery business grew 12%.

Automation Enabling Technologies segment revenue increased by 12%, driven by robotics and AI applications.

3Forward Guidance and Outlook

Full Year 2026 Guidance:

GAAP revenue expected to be $1.13 billion to $1.14 billion, indicating over 15% growth.

Adjusted EBITDA projected between $273 million and $278 million (24% to 26% growth).

Adjusted diluted EPS forecasted in the range of $3.68 to $3.74 (12% to 14% growth).

Q3 2026 Expectations:

GAAP revenue of $300 million to $304 million (21% to 23% growth).

Adjusted EBITDA between $74 million and $77 million (27% to 33% increase YoY).

4Bad News, Challenges, or Points of Concern

Precision Medicine Segment: Expected to decline in Q3 due to challenges in the life sciences market, which is anticipated to remain under pressure until 2027.

Gross Margin Pressures: Although margins improved, ongoing costs related to operational transformation and tariffs are expected to continue impacting margins.

Integration Risks: The transition of Riverpoint Medical into a public company poses potential challenges, particularly regarding revenue recognition and operational alignment.

5Notable Q&A Insights

Organic Growth Drivers: The Automation Enabling Technologies segment showed stronger performance, contributing to improved guidance.

Humanoid Robotics Orders: Initial significant orders for humanoid robotics were noted, indicating a shift from prototyping to training phases, though still in early stages.

Riverpoint Contribution: Expected to contribute approximately $35 million in revenue for Q3, with conservative estimates for the fourth quarter due to the company's transition to public operations.

R&D Spending: Decreased to about 9% of sales, with expectations to increase with the inclusion of Riverpoint's operations. Overall, Novanta demonstrated strong performance in Q2 2026, with solid growth across its segments and a significant acquisition poised to enhance future growth. However, challenges in specific markets and integration risks remain points of concern.